8-K: Neumora Advances Neuroscience Pipeline, Targets Key Milestones

Neumora Therapeutics unveils a robust pipeline update, highlighting promising clinical progress and strategic milestones across its metabolic, neurogenerative, and neuropsychiatric franchises, supported by a cash runway into Q3 2027.

Summary

• We are focused on bringing forward the next generation of novel therapies with brain-penetrant chemistry to improve treatment outcomes and quality of life for patients.
• Our pipeline includes three core franchises: Metabolic Disease (NMRA-215 for obesity), Neurogenerative Disease (NMRA-511 for Alzheimer's agitation, NMRA-GCASE for Parkinson's, NMRA-CK1 for ALS/Parkinson's), and Neuropsychiatric Disease (Navacaprant for Major Depressive Disorder, NMRA-898/NMRA-861 for Schizophrenia).
• We are well-capitalized with a cash runway expected to support operations into the third quarter of 2027.
• Multiple key catalysts are anticipated in 2026 across all three core franchises, including clinical trial initiations and data readouts.
• NMRA-215, an NLRP3 inhibitor for obesity, demonstrated up to 19% weight loss as monotherapy and up to 26% in combination with semaglutide in preclinical studies, matching semaglutide induction while preserving lean mass.
• NMRA-511, a V1aR antagonist for agitation in Alzheimer's Disease, showed a favorable tolerability and safety profile in Phase 1b, with an unsurpassed clinical effect size on CMAI total score in patients with elevated anxiety (Cohen's d 0.45-0.54).
• Navacaprant, a KOR antagonist for Major Depressive Disorder, is currently in Phase 3 development with joint topline data from KOASTAL-2 and -3 expected in Q2 2026.
• Our M4 PAM franchise (NMRA-861 and NMRA-898) for schizophrenia shows potential for best-in-class potency and optimized brain penetration compared to competitors, with no preclinical convulsions observed.

Sentiment

Score: 8

Explanation: The presentation outlines a robust pipeline with promising preclinical and early clinical data, addressing large unmet medical needs. The company is well-capitalized with a clear roadmap of catalysts for 2026, indicating strong operational momentum and potential for significant value creation.

Positives

• NMRA-215 for obesity demonstrated class-leading weight loss (up to 19% monotherapy, 26% combination) and matches semaglutide induction while preserving lean mass and improving metabolic biomarkers.
• NMRA-215 offers potential advantages over approved incretin therapies, including improved tolerability, oral administration, lower COGS, and no cold chain storage.
• NMRA-511 for Alzheimer's agitation was well-tolerated in Phase 1b, showing an unsurpassed clinical effect size in patients with elevated anxiety (Cohen's d 0.45-0.54) and a favorable safety profile compared to existing treatments.
• Navacaprant for Major Depressive Disorder utilizes a novel mechanism of action (KOR antagonism) with potential to treat anhedonia, addressing a significant unmet need.
• The M4 PAM franchise (NMRA-861, NMRA-898) for schizophrenia exhibits potential best-in-class potency and optimized brain penetration, differentiating from competitors like emraclidine.
• We are well-capitalized with a cash runway extending into the third quarter of 2027, providing financial stability for ongoing operations and clinical development.
• The pipeline addresses large market opportunities: obesity (~$130-$170 billion by 2030), Alzheimer's agitation (~7 million U.S. adults), Major Depressive Disorder (~21 million U.S. adults), and schizophrenia (~3 million U.S. patients).
• Multiple significant clinical catalysts are expected in 2026 across all three core franchises, indicating active progress and potential value inflection points.

Negatives

• Approved incretin therapies for obesity are associated with significant adverse events (nausea, vomiting, constipation, diarrhea), high discontinuation rates, weight regain, and require cold chain storage.
• The only currently approved therapy for Alzheimer's disease agitation carries a boxed warning for mortality in elderly people with dementia-related psychosis.
• Many individuals with Major Depressive Disorder (60-85%) experience inadequate response to monotherapy or fail to achieve remission with first-line treatment.
• Competitor M4 PAM, emraclidine, has shown disconnected receptor occupancy from plasma exposures in human PET studies, suggesting potential limitations in brain engagement.

Risks

• The inherent uncertainty of clinical drug development and the unpredictability and lengthy process for obtaining regulatory approvals.
• Risks related to the timely initiation and enrollment in our clinical trials.
• Reliance on third parties, including contract research organizations, for aspects of our development programs.
• Potential for serious or undesirable side effects from our therapeutic candidates.
• Our ability to effectively utilize and protect our intellectual property rights.
• The sufficiency of our capital resources to fund ongoing operations and development activities.

Future Outlook

We anticipate multiple catalysts in 2026 across our three core franchises, including the initiation of NMRA-215's clinical program in 1H 2026 with human proof-of-concept weight loss data expected by year-end 2026. We also expect joint topline data for Navacaprant's KOASTAL-2 and -3 trials in 2Q 2026, an M4 franchise update by mid-2026, and NMRA-511 MAD extension data by year-end 2026. Our mission is to bring forward next-generation novel therapies that offer improved treatment outcomes and quality of life for patients across large unmet medical needs.

Management Comments

• Our mission is to bring forward the next generation of novel therapies with brain-penetrant chemistry that offer improved treatment outcomes and quality of life for patients.
• We are led by experienced company builders and leading neuroscience drug developers.

Industry Context

Neuropsychiatric and neurodegenerative diseases, alongside metabolic disorders like obesity, represent some of the biggest health challenges in the U.S., impacting over 100 million patients. The global obesity market is projected to reach $130-$170 billion by 2030, with 1.13 billion people worldwide living with obesity. Alzheimer's disease agitation affects approximately 7 million U.S. adults, and Major Depressive Disorder is the leading cause of disability worldwide, impacting 280 million people globally. Many existing treatments for these conditions suffer from significant side effects, tolerability issues, or inadequate response rates, highlighting substantial unmet medical needs that our pipeline aims to address with differentiated, brain-penetrant therapies.

Comparison to Industry Standards

• NMRA-215 monotherapy demonstrated up to 19% weight loss, matching semaglutide induction, and showed class-leading weight loss compared to other NLRP3 inhibitors (VTX3232, VENT-02, BGE-102, NT-0796).
• NMRA-215 offers potential for better tolerability, oral convenience, lower COGS, and no cold chain storage compared to approved incretin therapies like semaglutide.
• NMRA-511 demonstrated a CMAI effect size similar to Auvelity in the total population and an unsurpassed effect size (Cohen's d 0.45-0.54) in patients with elevated anxiety, with a favorable tolerability profile compared to the only currently approved therapy for AD agitation which carries a boxed warning for mortality.
• NMRA-861 and NMRA-898 (M4 PAMs) show potential for best-in-class potency (e.g., M4 EC50 of 6 nM and 13 nM respectively, versus emraclidine's 26 nM) and optimized brain penetration, unlike emraclidine which has shown disconnected receptor occupancy from plasma exposures.

Stakeholder Impact

• Shareholders: Potential for significant value creation driven by multiple clinical catalysts in 2026 and a strong cash runway, addressing large market opportunities.
• Patients: Potential for improved treatment outcomes and quality of life through novel therapies with better tolerability and efficacy profiles across metabolic, neurogenerative, and neuropsychiatric diseases.
• Caregivers: Easier-to-maintain treatments, particularly for conditions like Alzheimer's agitation, could reduce caregiver burden.

Next Steps

• Report 12-week DIO mouse data for NMRA-215 in 1Q 2026.
• Initiate clinical program with NMRA-215 in monotherapy and combination settings in 1H 2026.
• Deliver proof of concept weight loss data for NMRA-215 around the end of 2026.
• Report KOASTAL-2 and -3 topline data (joint readout) for Navacaprant in 2Q 2026.
• Provide M4 franchise update by mid-2026.
• Report NMRA-511 MAD extension data year-end 2026.

Key Dates

Recommendation

Neumora Therapeutics is strategically positioned with a diversified pipeline targeting large, unmet medical needs in neuroscience and metabolic diseases. The presented preclinical and early clinical data for NMRA-215, NMRA-511, and the M4 PAMs demonstrate promising efficacy and tolerability profiles, often suggesting differentiation and potential superiority over existing treatments and competitors. The company's robust cash runway into Q3 2027 provides financial stability to execute on its numerous upcoming clinical milestones in 2026, which are significant potential value drivers. The experienced leadership team further strengthens the investment thesis, making this an attractive opportunity for seasoned investors.

Keywords

Neuroscience, Drug Development, Obesity, Alzheimer's Disease, Agitation, Major Depressive Disorder, Schizophrenia, NLRP3 Inhibitor, V1aR Antagonist, KOR Antagonist, M4 Modulator, Clinical Trials, Biotech, Pharmaceuticals